KLRK1 and Miyoshi myopathy: We observed that NKG2D and DNAM-1 blocking antibodies considerably reduced NK and γδ T cell cytotoxicity to low-dose bortezomib-treated MM cells, whereas a control monoclonal antibody (mAb) did not decrease the cytotoxicity.